The reformulation conversation in this industry keeps defaulting to chemistry: which cannabinoid is still available, what can be swapped for what. Section 781 closes that line of thinking deliberately, and the more useful question is commercial.
Why the chemistry route is closed
Three clauses in Public Law 119-37, effective 12 November 2026, work together.
The finished-product cap is 0.4 mg combined total per container across THC and other cannabinoids with similar effects, including those “marketed to have similar effects”. Products are separately excluded if they contain cannabinoids not capable of being naturally produced by the plant. And excluded again if they contain cannabinoids that could be naturally produced but “were synthesized or manufactured outside the plant”.
Most substitution plans clear one of these and fail another. The third clause in particular describes how the alternative cannabinoid market actually manufactures, which is why it catches products that pass the milligram test comfortably.
The question worth asking instead
What proportion of your customers were buying the effect, and what proportion were buying the experience?
Almost every brand assumes it knows and very few have measured it. The answer determines, SKU by SKU, whether November is a reformulation or a discontinuation, and it is worth more than any amount of formulation work performed on the wrong assumption.
Places to find it: repeat purchase patterns on your lowest-dose SKUs, what your reviews actually praise, whether customers ask about flavour or about strength, and what your highest-frequency buyers have in common.
The three-way sort
SKUs that transition cleanly. Products where the aromatic and sensory character was the draw. Topicals sit here most naturally, since the category never depended on intoxication. So does anything bought for ritual, flavour or scent.
SKUs that transition with real work. Beverages, most obviously. The market is there and growing, but the reformulation is an emulsion rebuild rather than a subtraction.
SKUs that do not transition. Products whose entire proposition was potency. The honest strategic move is to say so internally and early, rather than spending two quarters proving it. Where a state-licensed cannabis market exists, that is where those products legally live.
What the aromatic profile now has to carry
When a cannabinoid is present, an approximate profile is adequate, because something else is dominating the experience. When it is not, the profile is the product and the customer evaluates it directly.
That raises the specification in three specific ways. Fidelity, because an approximation reads as generic with nothing beside it, which is the practical form of the difference between the three sourcing routes. Stability, because volatile monoterpenes leave first and a profile changes shape across shelf life rather than simply weakening. And consistency, because variance nobody noticed becomes the review.
None of these are new problems. They are problems that were previously survivable.
Positioning without the crutch
A product that used to sell on milligrams needs a different claim, and the temptation is to reach for wellness language. Resist it. Effects claims invite regulatory attention precisely when a category is under scrutiny, and this category is under scrutiny.
Flavour, aroma, provenance, craft and consistency are all defensible, verifiable and genuinely differentiating. They are also harder to fake, which is an advantage for anyone who has actually done the work.
What to do in August
Sort the SKUs three ways. Measure, do not assume, which customers were buying what. Requalify aromatic inputs on residual cannabinoid content and documentation standard. Start stability early, because it is the longest task. And begin the supplier conversations described in our due diligence brief while there is still negotiating room.
The Senate text released 2 August 2026 that would move most restrictions to 11 December had not passed as of 5 August. Even if it does, four weeks is not a product cycle.
About this brief
Written 5 August 2026 and checked against the statute and the Federal Register rather than against secondary coverage. This is a summary for commercial planning, not legal advice. Where the answer depends on your product format, your state or your licence position, take the specific question to your own counsel.
